Financial Solutions Advisory Group Inc. Purchases Shares of 5,069 Merck & Co., Inc. $MRK

Financial Solutions Advisory Group Inc. purchased a new position in Merck & Co., Inc. (NYSE:MRK) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 5,069 shares of the company’s stock, valued at approximately $610,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Chesapeake Wealth Management raised its stake in Merck & Co., Inc. by 0.6% in the 4th quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock worth $1,552,000 after acquiring an additional 87 shares during the last quarter. South Plains Financial Inc. grew its stake in Merck & Co., Inc. by 0.6% during the 4th quarter. South Plains Financial Inc. now owns 15,535 shares of the company’s stock valued at $1,635,000 after purchasing an additional 89 shares during the last quarter. Syverson Strege & Co grew its stake in Merck & Co., Inc. by 2.2% during the 4th quarter. Syverson Strege & Co now owns 4,142 shares of the company’s stock valued at $436,000 after purchasing an additional 90 shares during the last quarter. Nations Financial Group Inc. IA ADV increased its holdings in shares of Merck & Co., Inc. by 0.4% in the first quarter. Nations Financial Group Inc. IA ADV now owns 23,433 shares of the company’s stock valued at $2,819,000 after purchasing an additional 91 shares during the period. Finally, Westside Investment Management Inc. increased its holdings in shares of Merck & Co., Inc. by 3.1% in the fourth quarter. Westside Investment Management Inc. now owns 3,142 shares of the company’s stock valued at $331,000 after purchasing an additional 93 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of MRK opened at $130.49 on Friday. The business’s 50-day moving average is $123.17 and its two-hundred day moving average is $118.46. The company has a market capitalization of $322.28 billion, a P/E ratio of 36.76, a P/E/G ratio of 5.17 and a beta of 0.19. Merck & Co., Inc. has a fifty-two week low of $77.53 and a fifty-two week high of $135.05. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. During the same quarter in the previous year, the firm posted $2.22 EPS. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. Research analysts predict that Merck & Co., Inc. will post 2.74 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.6%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 95.77%.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck’s launch of subcutaneous Keytruda, known as Qlex, and other lifecycle extensions could preserve the drug’s commercial momentum and support exclusivity through 2039. Recent regulatory approvals, pipeline progress and the acquisitions of Terns and Cidara also broaden the company’s oncology and virology prospects. Merck: Heading Into Q2 Earnings, The Keytruda Cliff Looks Increasingly Less Steep
• Positive Sentiment: Analyst estimates have improved, including Erste Group’s modest increase in its FY2027 EPS forecast to $9.54 from $9.52. Barclays has also forecast strong potential appreciation for MRK, reinforcing the constructive sentiment around the shares. Barclays Forecasts Strong Price Appreciation for Merck & Co., Inc. Stock
• Positive Sentiment: Merck declared a quarterly dividend of $0.85 per share, payable October 7 to shareholders of record September 15. The dividend provides ongoing income support, with a reported annualized yield of about 2.6%.
• Neutral Sentiment: MRK is scheduled to release second-quarter 2026 results before the market opens on August 4. Consensus calls for approximately $16.33 billion in sales and a loss of $0.26 per share, with acquisition costs likely affecting reported earnings. Investors will watch Keytruda demand, Gardasil performance and management’s outlook. Should You Buy, Sell or Hold Merck Stock Ahead of Q2 Earnings?
• Neutral Sentiment: Merck and Wellcome’s Hilleman Laboratories are preparing an experimental Ebola vaccine for clinical trials. The initiative supports Merck’s public-health profile but is unlikely to materially affect near-term financial results. Merck, Wellcome Partner With Global Health Group to Make Ebola Vaccine for Clinical Trials
• Negative Sentiment: After a roughly 17% rally since its latest quarterly results, MRK may already reflect much of the favorable Keytruda and pipeline news. Analysts characterize its longer-term valuation as justified rather than clearly inexpensive, while Gardasil weakness and the approaching earnings event remain risks. Merck Stock Looks Cheap on Cash Flow but Fair on Earnings

Analyst Ratings Changes

Several research analysts have recently issued reports on MRK shares. Weiss Ratings cut Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. BMO Capital Markets upped their target price on Merck & Co., Inc. from $135.00 to $142.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Barclays increased their price target on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday. CICC Research assumed coverage on shares of Merck & Co., Inc. in a research report on Wednesday, June 24th. They set an “outperform” rating and a $138.00 price target for the company. Finally, Citigroup began coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price objective for the company. Thirteen equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $134.50.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.